bluebird bio (NASDAQ: BLUE) reported Q3 EPS of ($0.31), $0.05 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $10.6 million versus the consensus estimate of $18.05 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.